The effect of birch pollen immunotherapy on hazelnut allergy.

ISRCTN ISRCTN52709516
DOI https://doi.org/10.1186/ISRCTN52709516
Secondary identifying numbers NTR172
Submission date
20/12/2005
Registration date
20/12/2005
Last edited
18/11/2008
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Respiratory
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr K.A.B.M. Peeters
Scientific

University Medical Centre Utrecht
Department of Dermatology/Allergology
P.O. Box 85500
Utrecht
3508 GA
Netherlands

Phone +31 (0)30 250 7388
Email K.A.B.M.Peeters@umcutrecht.nl

Study information

Study designRandomised, double-blind, placebo controlled, parallel group trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Scientific titleThe effect of birch pollen immunotherapy on hazelnut allergy evaluated by DBPCFC with hazelnut
Study objectivesThe severity of hazelnut allergy will decrease as an additional effect by birch pollen immunotherapy.
Ethics approval(s)Received from the local medical ethics committee
Health condition(s) or problem(s) studiedPollen/hazelnut allergy
InterventionImmunotherapy with birch pollen extract.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Birch pollen extract
Primary outcome measureDBPCFC with hazelnut before immunotherapy with birch pollen and after 1 year.
Secondary outcome measures1. Skin prick tests
2. Serological analyses
Overall study start date01/04/2004
Completion date01/11/2005

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants19
Key inclusion criteriaPatients greater than 18 years with birch pollen allergy and hazelnut allergy
Key exclusion criteria1. Pregnancy
2. Significant concurrent disease
3. Instable asthma and oral medication with corticosteroids or beta-blocking agents
Date of first enrolment01/04/2004
Date of final enrolment01/11/2005

Locations

Countries of recruitment

  • Netherlands

Study participating centre

University Medical Centre Utrecht
Utrecht
3508 GA
Netherlands

Sponsor information

University Medical Centre Utrecht (UMCU) (The Netherlands)
Hospital/treatment centre

Department of Dermatology and Allergology
P.O. Box 85500
Utrecht
3508 GA
Netherlands

Phone +31 (0)30 250 7388
Email info@umcutrecht.nl
Website http://www.umcutrecht.nl
ROR logo "ROR" https://ror.org/04pp8hn57

Funders

Funder type

Industry

ALK-Abello BV (The Netherlands)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan